Jeff Stark, MD, is vice president and head of medical immunology, UCB. He is also a rheumatologist by training and leads UCB’s medical affairs team across the key focus areas of dermatology and rheumatology.
Bimekizumab-bkzx Expands Treatment Options for Inflammatory Conditions
Jeffrey Stark, MD, vice president and head of medical immunology at UCB, discusses tailored dosing of bimekizumab-bkzx (Bimzelx) for various inflammatory conditions, highlighting its 5 FDA approvals and the remaining challenges.